A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease | MicrobiomeTrials← Back to trialsNCT06925542
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2025-03-10Est. Completion: 2031-12-31
Enrollment target: 80 participants Locations- UC San Diego Health, La Jolla, California, United States
- Stanford University Medical Center, Redwood City, California, United States
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
- University of Iowa, Iowa City, Iowa, United States
- Tulane University Medical Center, New Orleans, Louisiana, United States
- Boston Medical Center, Boston, Massachusetts, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- University of North Carolina TraCS Institute - CTRC, Chapel Hill, North Carolina, United States
- Oregon Health Sciences University, Portland, Oregon, United States
- University of Augsburg, Augsburg, Germany
- Universitätsklinikum Köln, Cologne, Germany
- Medizinische Hochschule Hannover (MHH), Hanover, Germany
- UCT University Medical Center Mainz, Mainz, Germany
- Hospital Universitario Reina Sofia, Córdoba, Spain
- Clinica Universidad de Navarra - Pamplona, Pamplona, Spain
- Hospital Universitario Virgen del Rocio, Seville, Spain
Other microbiome trials you might be interested in
Autoimmune Diseases
Background:
Autoimmune diseases can be caused by genes people inherit from their parents. The gene changes that cause t…
Bethesda, United StatesEst. completion Apr 22, 2030
Systemic Lupus Erythematosus (Sle)Primary Ovarian Insufficiency (Poi)
Background:
Systemic lupus erythematosus (SLE) is a disease that affects females nine times more often than males. Peop…
Bethesda, United StatesEst. completion May 31, 2027
Hospital Clinico Universitario de Valencia, Valencia, SpainSystemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE) is an autoimmune rheumatic disease. Patients report that fatigue has a significant im…
Edinburgh, United KingdomEst. completion Mar 9, 2026